198 related articles for article (PubMed ID: 32633245)
1. [Androgen deprivation therapy in advanced prostate cancer. Multicenter study.].
Valencia-Guadalajara VJ; Martínez-Cayuelas L; Sarrió-Sanz P; Sánchez-Caballero L; Polo-Hernández R; Chillón-Sempere FS; Galán-Llopis JA; Garcés-Valverde M; Tenza-Tenza JA; Costa-Martínez A; García Serrado-Paumard D; Escudero-Fontana E; Tello-Royloa C; Verdú-Verdú LP; Bravo-López DF; Pérez Seoane-Ballester H; Pacheco-Bru JJ; Ortiz-Gorraiz MÁ
Arch Esp Urol; 2020 Jul; 73(6):499-508. PubMed ID: 32633245
[TBL] [Abstract][Full Text] [Related]
2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
3. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
4. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
5. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
6. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.
Garcia-Rodriguez J; Fernandez-Gomez JM; Cozar JM; Miñana B; Gomez-Veiga F; Rodriguez-Antolin A; ;
Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):156-163. PubMed ID: 32113829
[TBL] [Abstract][Full Text] [Related]
8. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
9. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
10. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
Song C; Kim YS; Hong JH; Kim CS; Ahn H
BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
[TBL] [Abstract][Full Text] [Related]
11. Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients.
Qu M; Zhu F; Chen H; Lian B; Jia Z; Shi Z; Li J; Wang Y; Sun Y; Gao X
J Endourol; 2019 Jul; 33(7):570-575. PubMed ID: 31025578
[No Abstract] [Full Text] [Related]
12. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
13. Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression.
Salciccia S; Frisenda M; Tufano A; Di Pierro G; Bevilacqua G; Rosati D; Gobbi L; Basile G; Moriconi M; Mariotti G; Forte F; Carbone A; Pastore A; Cattarino S; Sciarra A; Gentilucci A
Clin Genitourin Cancer; 2024 Apr; 22(2):74-83. PubMed ID: 37758559
[TBL] [Abstract][Full Text] [Related]
14. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
[TBL] [Abstract][Full Text] [Related]
15. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
Huang FM; Li XH; Liang Y
Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
[TBL] [Abstract][Full Text] [Related]
16. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
[TBL] [Abstract][Full Text] [Related]
17. Metastasic Prostate Cancer: Predictive Factors of Earlier Progression to Castration-Resistance.
Dellavedova T; Malizia E; Quinteros L; Nobile R; Minuzzi F
Arch Esp Urol; 2022 Jun; 75(5):430-434. PubMed ID: 35983814
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
[TBL] [Abstract][Full Text] [Related]
19. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer.
Benaim EA; Pace CM; Lam PM; Roehrborn CG
Urology; 2002 Jan; 59(1):73-8. PubMed ID: 11796285
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
Xu Z; Wei F; Wang J; Ma S; Kan Y; Li B; Qi N; Mao L
Cancer Med; 2023 Feb; 12(4):4352-4356. PubMed ID: 36106643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
